{"id":"pilocarpine-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Miosis (pupil constriction)"},{"rate":null,"effect":"Accommodative spasm (blurred vision)"},{"rate":null,"effect":"Ocular irritation and discomfort"},{"rate":null,"effect":"Brow ache"},{"rate":null,"effect":"Conjunctival hyperemia"}]},"_chembl":null,"_dailymed":{"setId":"84428e9a-f486-44d9-ad93-4ea9069a6787","title":"PILOCARPINE HYDROCHLORIDE (PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION) SOLUTION/ DROPS [SOMERSET THERAPEUTICS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pilocarpine binds to muscarinic M3 receptors on the ciliary muscle and iris sphincter muscle, causing contraction (miosis and accommodation). This mechanical action opens the trabecular meshwork and Schlemm's canal, facilitating drainage of aqueous humor and lowering intraocular pressure. It is a direct-acting parasympathomimetic agent used topically in ophthalmology.","oneSentence":"Pilocarpine is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity in the eye to increase aqueous humor outflow and reduce intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:19.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma and ocular hypertension"},{"name":"Acute angle-closure glaucoma"}]},"trialDetails":[{"nctId":"NCT05646719","phase":"PHASE3","title":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2022-12-22","conditions":"Presbyopia","enrollment":333},{"nctId":"NCT03933631","phase":"PHASE3","title":"Pilocarpine Use After Kahook Goniotomy","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2019-05-01","conditions":"Glaucoma","enrollment":142},{"nctId":"NCT04675151","phase":"PHASE2","title":"Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2021-02-15","conditions":"Presbyopia","enrollment":150},{"nctId":"NCT06783686","phase":"EARLY_PHASE1","title":"Evaluation of NV701 (Pilocarpine 1.25%) Compared With Vuity (Pilocarpine 1.25%) on Pupil Size in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Novus Vision LLC","startDate":"2025-01-30","conditions":"Pupil Constriction","enrollment":55},{"nctId":"NCT07113210","phase":"PHASE4","title":"Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","status":"RECRUITING","sponsor":"Southern College of Optometry","startDate":"2025-07-18","conditions":"Presbyopia, Glasses, Dry Eye","enrollment":36},{"nctId":"NCT07012512","phase":"NA","title":"Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in Children","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-06-01","conditions":"Pupillary Constriction, Accomodation","enrollment":60},{"nctId":"NCT06752278","phase":"NA","title":"Efficacy of Pilocarpine As a Secretagogue Versus Artificial Tears for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-10-01","conditions":"Dry Eye Disease (DED)","enrollment":40},{"nctId":"NCT04837482","phase":"PHASE3","title":"A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-05-14","conditions":"Presbyopia","enrollment":43},{"nctId":"NCT06451666","phase":"PHASE3","title":"Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With Presbyopia","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-06-30","conditions":"Presbyopia","enrollment":330},{"nctId":"NCT05114486","phase":"PHASE3","title":"Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults","status":"COMPLETED","sponsor":"Eyenovia Inc.","startDate":"2021-11-03","conditions":"Presbyopia","enrollment":145},{"nctId":"NCT04741919","phase":"NA","title":"Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS)","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-11-25","conditions":"Primary Angle Glaucoma Closure Suspect","enrollment":200},{"nctId":"NCT04983589","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily","status":"COMPLETED","sponsor":"Allergan","startDate":"2021-09-02","conditions":"Presbyopia","enrollment":230},{"nctId":"NCT05238233","phase":"PHASE4","title":"Wearing-Off Period of Pharmacological Dilation and Anisocoria","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2022-04-01","conditions":"Anisocoria","enrollment":11},{"nctId":"NCT05564832","phase":"EARLY_PHASE1","title":"Pharmacological Treatment of Presbyopia","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2022-08-01","conditions":"Near Vision","enrollment":75},{"nctId":"NCT05231928","phase":"NA","title":"A Novel Argon Laser Iridoplasty for Pigment Dispersion Syndrome","status":"UNKNOWN","sponsor":"Fayoum University","startDate":"2021-12-01","conditions":"Pigment Dispersion Syndrome, Pigmentary Glaucoma","enrollment":10},{"nctId":"NCT05393089","phase":"PHASE2","title":"Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2022-06-09","conditions":"Presbyopia","enrollment":""},{"nctId":"NCT05352854","phase":"NA","title":"Morphological Changes of Ciliary Body and Trabecular Meshwork","status":"UNKNOWN","sponsor":"Yune Zhao","startDate":"2022-05-01","conditions":"Glaucoma, Myopia","enrollment":120},{"nctId":"NCT02865473","phase":"NA","title":"Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2016-04-20","conditions":"Glaucoma","enrollment":90},{"nctId":"NCT05241938","phase":"NA","title":"PSLT Compared to Prostaglandin Analogue Eye Drops","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2021-09-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":75},{"nctId":"NCT03857542","phase":"PHASE3","title":"A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-03-01","conditions":"Presbyopia","enrollment":427},{"nctId":"NCT03804268","phase":"PHASE3","title":"Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2018-12-21","conditions":"Presbyopia","enrollment":323},{"nctId":"NCT05006898","phase":"PHASE1","title":"Compound to Control Presbyopia Symptoms","status":"COMPLETED","sponsor":"Optall Vision","startDate":"2020-06-01","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT05001243","phase":"PHASE1","title":"Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients","status":"UNKNOWN","sponsor":"Optall Vision","startDate":"2021-08-10","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT04657172","phase":"PHASE3","title":"Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults","status":"COMPLETED","sponsor":"Eyenovia Inc.","startDate":"2020-12-15","conditions":"Presbyopia","enrollment":84},{"nctId":"NCT04195100","phase":"EARLY_PHASE1","title":"Local Pilocarpine for Relieving Dry Mouth","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2019-04-01","conditions":"Patients of Advanced Age (≥ 70 Years) With a Clinical Diagnosis of Chronic Dry Mouth","enrollment":14},{"nctId":"NCT03753009","phase":"","title":"Iontophoretic Transepithelial Collagen Cross-linking Versus Epithelium-off Collagen Cross-linking in Pediatric Patients. Three Year Follow up.","status":"COMPLETED","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2013-01-01","conditions":"Keratoconus","enrollment":28},{"nctId":"NCT01627626","phase":"NA","title":"Effect of 0.1% Pilocarpine Mouthwash on Xerostomia","status":"COMPLETED","sponsor":"Jeong-seong Kwon","startDate":"2011-08","conditions":"Xerostomia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glaupin 1%","MicroLine","AGN-190584","VUITY"],"phase":"marketed","status":"active","brandName":"Pilocarpine Ophthalmic Solution","genericName":"Pilocarpine Ophthalmic Solution","companyName":"Maastricht University Medical Center","companyId":"maastricht-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pilocarpine is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity in the eye to increase aqueous humor outflow and reduce intraocular pressure. Used for Glaucoma and ocular hypertension, Dry eye syndrome (xerophthalmia).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}